Biohaven Pharmaceutical Holding Company Ltd. Research and Development Expense
Biohaven Pharmaceutical Holding Company Ltd. reported Research and Development Expense of $218.48 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-05
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for the quarter ending 2022-06-30 was $218.48M, a 182.17% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for the quarter ending 2022-03-31 was $119.10M, a 11.19% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for the quarter ending 2021-12-31 was $91.14M, a 24.07% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for the quarter ending 2021-09-30 was $85.66M, a 50.17% increase year-over-year.
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for fiscal 2021 was $361.34M, a 57.79% increase from fiscal 2020.
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for fiscal 2020 was $229.00M, a 33.56% decline from fiscal 2019.
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for fiscal 2019 was $344.67M, a 81.45% increase from fiscal 2018.
- Biohaven Pharmaceutical Holding Company Ltd. research and development expense for fiscal 2018 was $189.95M, a 112.38% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $218.48M 10-Q · filed 2022-08-05 | $337.58M 10-Q · filed 2022-08-05 | $428.72M derived: sum of 3 quarters · filed 2022-08-05 | $514.38M derived: sum of 4 quarters · filed 2022-08-05 |
| 2022-03-31 | $119.10M 10-Q · filed 2022-05-10 | $210.24M derived: sum of 2 quarters · filed 2022-05-10 | $295.90M derived: sum of 3 quarters · filed 2022-05-10 | $373.33M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-12-31 | $91.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $176.80M derived: sum of 2 quarters · filed 2022-02-25 | $254.23M derived: sum of 3 quarters · filed 2022-08-05 | $361.34M 10-K · filed 2022-02-25 |
| 2021-09-30 | $85.66M 10-Q · filed 2021-11-09 | $163.09M derived: sum of 2 quarters · filed 2022-08-05 | $270.20M 10-Q · filed 2021-11-09 | $343.66M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-06-30 | $77.43M 10-Q · filed 2022-08-05 | $184.54M 10-Q · filed 2022-08-05 | $258.00M derived: sum of 3 quarters · filed 2022-08-05 | $315.04M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $107.11M 10-Q · filed 2022-05-10 | $180.57M derived: sum of 2 quarters · filed 2022-05-10 | $237.61M derived: sum of 3 quarters · filed 2022-05-10 | $280.04M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $73.46M 10-K · filed 2021-03-01 | $130.50M derived: sum of 2 quarters · filed 2021-11-09 | $172.93M derived: sum of 3 quarters · filed 2021-11-09 | $229.00M 10-K · filed 2022-02-25 |
| 2020-09-30 | $57.04M 10-Q · filed 2021-11-09 | $99.47M derived: sum of 2 quarters · filed 2021-11-09 | $155.54M 10-Q · filed 2021-11-09 | $221.56M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $42.42M 10-Q · filed 2021-08-09 | $98.50M 10-Q · filed 2021-08-09 | $164.51M derived: sum of 3 quarters · filed 2021-08-09 | $226.19M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $56.07M 10-Q · filed 2021-05-10 | $122.09M derived: sum of 2 quarters · filed 2021-05-10 | $183.76M derived: sum of 3 quarters · filed 2021-05-10 | $359.74M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $66.02M 10-K · filed 2021-03-01 | $127.69M derived: sum of 2 quarters · filed 2021-03-01 | $303.67M derived: sum of 3 quarters · filed 2021-03-01 | $344.67M 10-K · filed 2022-02-25 |
| 2019-09-30 | $61.67M 10-K · filed 2021-03-01 | $237.65M derived: sum of 2 quarters · filed 2021-03-01 | $278.65M 10-Q · filed 2020-11-09 | $316.61M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $175.98M 10-K · filed 2021-03-01 | $216.98M 10-Q · filed 2020-08-10 | $254.94M derived: sum of 3 quarters · filed 2021-03-01 | $302.30M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $41.00M 10-K · filed 2021-03-01 | $78.96M derived: sum of 2 quarters · filed 2021-03-01 | $126.32M derived: sum of 3 quarters · filed 2021-03-01 | $155.38M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $37.96M 10-K · filed 2020-02-26 | $85.32M derived: sum of 2 quarters · filed 2020-02-26 | $114.37M derived: sum of 3 quarters · filed 2020-02-26 | $189.95M 10-K · filed 2021-03-01 |
| 2018-09-30 | $47.36M 10-K · filed 2020-02-26 | $76.41M derived: sum of 2 quarters · filed 2020-02-26 | $151.99M 10-Q · filed 2019-11-01 | $174.68M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $29.05M 10-K · filed 2020-02-26 | $104.63M 10-Q · filed 2019-08-09 | $127.32M derived: sum of 3 quarters · filed 2020-02-26 | $162.31M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $75.58M 10-K · filed 2020-02-26 | $98.27M derived: sum of 2 quarters · filed 2020-02-26 | $133.26M derived: sum of 3 quarters · filed 2020-02-26 | $154.28M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $22.69M 10-K · filed 2019-02-28 | $57.68M derived: sum of 2 quarters · filed 2019-02-28 | $78.70M derived: sum of 3 quarters · filed 2019-02-28 | $89.44M 10-K · filed 2020-02-26 |
| 2017-09-30 | $35.00M 10-K · filed 2019-02-28 | $56.02M derived: sum of 2 quarters · filed 2019-02-28 | $66.75M 10-Q · filed 2018-11-14 | $87.15M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $21.02M 10-K · filed 2019-02-28 | $31.76M 10-Q · filed 2018-08-14 | $52.15M derived: sum of 3 quarters · filed 2019-02-28 | $79.20M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $10.74M 10-K · filed 2019-02-28 | $31.13M derived: sum of 2 quarters · filed 2019-02-28 | $58.18M derived: sum of 3 quarters · filed 2019-02-28 | $63.90M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $20.39M 10-K · filed 2018-03-06 | $47.44M derived: sum of 2 quarters · filed 2018-03-06 | $53.16M derived: sum of 3 quarters · filed 2018-03-06 | $55.53M 10-K · filed 2019-02-28 |
| 2016-09-30 | $27.05M 10-K · filed 2018-03-06 | $32.77M derived: sum of 2 quarters · filed 2018-03-06 | $35.14M 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $5.72M 10-K · filed 2018-03-06 | $8.09M 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $2.37M 10-K · filed 2018-03-06 | |||
| 2015-12-31 | $7.56M 10-K · filed 2018-03-06 |